Alamar Biosciences, Inc. (NASDAQ:ALMR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Alamar Biosciences, Inc. (NASDAQ:ALMR) have received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $30.00.

ALMR has been the subject of several research reports. Bank of America started coverage on Alamar Biosciences in a report on Tuesday, May 12th. They issued a “neutral” rating and a $27.00 target price for the company. Zacks Research raised Alamar Biosciences to a “hold” rating in a research report on Wednesday, May 13th. Wall Street Zen raised Alamar Biosciences to a “hold” rating in a research report on Saturday, April 25th. Leerink Partners started coverage on Alamar Biosciences in a research report on Tuesday, May 12th. They issued an “outperform” rating and a $35.00 price target for the company. Finally, TD Cowen started coverage on Alamar Biosciences in a research report on Tuesday, May 12th. They issued a “buy” rating and a $30.00 price target for the company.

Insider Buying and Selling at Alamar Biosciences

In related news, Director Nicholas Naclerio purchased 235,294 shares of Alamar Biosciences stock in a transaction dated Monday, April 20th. The stock was purchased at an average cost of $17.00 per share, with a total value of $3,999,998.00. Following the transaction, the director owned 507,076 shares in the company, valued at approximately $8,620,292. The trade was a 86.57% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Innovation Fund Gp Illumina II purchased 235,294 shares of Alamar Biosciences stock in a transaction dated Monday, April 20th. The stock was bought at an average cost of $17.00 per share, with a total value of $3,999,998.00. Following the completion of the transaction, the insider owned 507,076 shares in the company, valued at approximately $8,620,292. This represents a 86.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Alamar Biosciences Price Performance

Shares of ALMR stock opened at $27.09 on Wednesday. Alamar Biosciences has a twelve month low of $18.84 and a twelve month high of $28.68. The stock has a fifty day moving average price of $22.49.

Alamar Biosciences (NASDAQ:ALMR) last issued its earnings results on Friday, May 8th. The company reported ($1.74) earnings per share for the quarter. The business had revenue of $26.04 million during the quarter.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.